الولايات المتحدة · مجلات اقتصادية · Quartz

Germany's Merck KGaA is buying U.K. gene-silencing biotech for $1.3 billion

نشره Quartz · الولايات المتحدة منذ 3 س

The all-cash deal adds divesiran, an experimental rare-disease drug ready for late-stage trials, to Merck KGaA's pipeline

اقرأ المقال كاملًا على Quartz سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (qz.com)

يستحق القراءة أيضًا

Your Company Doesn’t Need More AI Tools. It Needs These 6 Operating Changes

Ex-OpenAI engineer accused of bugging office stays in jail as prosecutors allege Saudi ties: ‘Once he leaves, there’s no getting him back’

Markets Insider (Business Insider)

Stanley Roof and Solar Releases Inspection-Based Guidance for Roof Repair and Replacement Decisions in Vancouver, WA

Nasdaq Bounces Back as AI Trade Freshens Up: Stock Market Today

This startup died in 2017, but its dream of in-ear computing is everywhere

Hiring a Speaker for Your Next Event? Ask These 6 Questions Before You Sign a Contract